1.Date of the resolution by the board of directors or decision by the Company: 2022/01/25
2.Number of shares issued: 30,000,000 common shares
3.Par Value per share: 10 NTD
4.Total monetary value of the issuance: 300,000,000 NTD
5.Issue price:
The actual issue price will be determined and announced pursuant to Article 6 of Taiwan Securities Association Self-regulatory Rules Governing the Provision of Advisory Services by Underwriter Members to Issuing Companies Offering and Issuing Securities.
6.Number of shares subscribed for by employees:
Pursuant to Article 267 of the Company Act, 15% (4,500,000 shares) of the total new shares are reserved for employees who are eligible.
7.Ratio of shares subscribed for by existing shareholders:
75% (22,500,000 shares) of the total new shares (112.90681794 shares per thousand shareholdings) will be subscribed by original shareholders based on the shareholding ratio stated on the register of shareholders on the reference date.
8.Method for public sale and no.of shares:
Pursuant to Article 28-1 of the Securities Exchange Act, 10% (3,000,000 shares) of the total new shares will be publicly underwritten.
9.Handling method for fractional shares and shares unsubscripted for by the deadline:
The original shareholder may apply to the stock transfer agent of the company within five days from the date for book closure to combine fractional shares into full shares. For fractional shares that fall short of full shares and shares that original shareholders and employees forfeit or insufficiently subscribe, the Chairman is authorized to contact designated persons for purchase at the issue price.
10.Rights and obligations of these newly issued shares:
Rights and obligations of the issued shares are the same as existing common shares.
11.Utilization of the funds from the current capital increase:
Support new drug research and development and enrich working capital.
12.Reference date of cash capital increase and share subscription: 2022/2/26
13.Last date before book closure: 2022/2/21
14.Book closure starting date: 2022/2/22
15.Book closure ending date: 2022/2/26
16.Payment period:
(1)Payment period for existing shareholders and employees: 2022/3/4 ~ 2022/3/17
(2)Payment period for designated persons: 2022/3/18 ~ 2022/3/24
17.Date of the agreement with the banks to collect and deposit the proceeds:
Announcement to be made after contract execution.
18.Name of the institution designated to collect the proceeds:
Announcement to be made after contract execution.
19.Name of the bank designated to deposit the proceeds:
Announcement to be made after contract execution.
20.Any other matters that need to be specified:
The capital increase through the issuance of new shares was approved by the Financial Supervisory Commission on January 18, 2022, approval letter No. 1100378381.